# TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

> **NCT04760431** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 120 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Brain Metastases

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Taxanes
- **DRUG:** Pertuzumab
- **DRUG:** Tyrosine kinase inhibitor

## Key facts

- **NCT ID:** NCT04760431
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2021-06-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04760431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04760431, "TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04760431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*